Similar articles

• [Significance of fibrinuria for the evolution of treated glomerulonephritis].

  Michielsen P, Roels L, Vanrenterghem Y, Boel A, Van Damme B, Vermylen J. Michielsen P, et al. J Urol Nephrol (Paris). 1975 Apr-May;81(4-5):269-80. J Urol Nephrol (Paris). 1975. PMID: 1159886 French. No abstract available.
• Treatment of chronic glomerulonephritis with a combination of indomethacin and cyclophosphamide.

  Vanrenterghem Y, Roels L, Verberckmoes R, Michielsen P. Vanrenterghem Y, et al. Clin Nephrol. 1975 Dec;4(6):218-22. Clin Nephrol. 1975. PMID: 1204260
• Significance of urinary excretion of fibrin degradation products during treatment of glomerulonephritis.

  Michielsen P, Roels L, Vanrenterghem Y, Boel A, van Damme B, Vermylen J. Michielsen P, et al. Clin Nephrol. 1976 Mar;5(3):105-13. Clin Nephrol. 1976. PMID: 1261101
• [Therapy of rapidly progressive glomerulonephritis].

  Röckel A, Romen W, Heidland A. Röckel A, et al. Dtsch Med Wochenschr. 1982 Oct 8;107(40):1521-5. doi: 10.1055/s-2008-1070160. Dtsch Med Wochenschr. 1982. PMID: 6749470 Review. German. No abstract available.
• [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].

  Pozzi C, Del Vecchio L, Locatelli F. Pozzi C, et al. G Ital Nefrol. 2002 Sep-Oct;19(5):523-8. G Ital Nefrol. 2002. PMID: 12439840 Review. Italian.